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RESULTS: In the base case, a pharmaceutical care beneﬁt
in the elderly population would cost $6312 (year 2000
prices) per life year saved-highly cost-effective. Aside
from the number of deaths that are medication-related,
no individual variations in parameters raised the cost-
effectiveness ratio above $10,982 per life year saved.
CONCLUSION: Despite data limitations, pharmaceuti-
cal care appears to be a highly cost effective augmenta-
tion to a Medicare drug beneﬁt program. This result is
insensitive to model parameter changes. This model is
conservative in that it does not include ongoing beneﬁts
from medication monitoring, or increased elderly drug
utilization and polypharmacy as the Medicare drug
program is phased in.
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OBJECTIVES: This study focuses on the use of a new
analytical tool, the Generic Prescribing Index (GPI), as a
tool for healthcare cost containment. An illustrative cost
analysis was performed using a statewide Medicaid data-
base to demonstrate the utility of the GPI concept. The
GPI is the ratio between the total number of generic pre-
scriptions within a therapeutic class divided by the total
number of prescriptions within the therapeutic class.
METHODS: A retrospective data analysis was conducted
to analyze the prescribing of cimetidine, ranitidine, famo-
tidine, and nizatidine statewide to assess the ﬁnancial
impact of brand name prescribing for H2 blockers. H2
blocker prescription data for SFY 2000 came from the
state Medicaid database. Descriptive statistics were cal-
culated. The GPI was calculated for the state, each region
of the state, and each primary care physician in the 
Medicaid program.
RESULTS: The GPI for the state was 0.4319, meaning
approximately 43% of H2 blockers prescribed were
generic products. In over 20 counties, the brand name
famotidine prescribing rate was over 50%. The use of
brand name famotidine resulted in over $2 million in
added expenditures (during the study period), which
could have been freed up for alternative uses if ranitidine
had become the medication of choice for H2 blocker 
prescribing.
CONCLUSION: The Generic Prescribing Index provides
a model for future use in other therapeutic classes (e.g.,
proton pump inhibitors, ace inhibitors) with similar
potential for therapeutic substitution. It is an inexpen-
sive method to analyze prescription drug patterns and
perform economic analysis. It may be useful in develop-
ing prior authorization programs and promoting cost-
effective prescribing. The GPI information may be used
in counter-detailing programs to illustrate the importance
of selecting a medication with a generic substitute within
a therapeutic class, if appropriate for the patient.
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OBJECTIVE: To explore whether payment mechanisms
for the treatment of conditions often reimbursed outside
of the health-care industry could beneﬁt by incorporation
of severity or case-mix adjustments.
METHODS: Data were culled from a fully integrated
medical and pharmacy claims database, and were
obtained on acute treatment episodes for all skin and soft
tissue injuries, major/minor trauma, and fractures over a
two-year period (N = 4.8 million). Episodes were strati-
ﬁed by type; selected comorbidities (arthritis, diabetes,
osteoporosis) and complications (device/graft failure,
post-operative infection or hemorrhage) thought to
potentially affect recovery and hence total utilization and
costs were identiﬁed. Measures of interest were estimated
at an episode level, and included total episode duration
(in days), number of services provided, and total billed
charges. Measures were analyzed using techniques of
multiple linear regression; in addition to markers for 
complications and comorbidities, independent variables
included age, gender, and geographic region.
RESULTS: While absolute measures of episode duration,
utilization, and charges increased with age for patients
with comorbidity or complication diagnoses, the inde-
pendent effects of these conditions decreased in older 
age groups; in particular, effect sizes in patients aged 
≥ 65 years were minimal. Among individual conditions
for patients aged <65 years, arthritis and osteoporosis
were generally found to signiﬁcantly increase episode
duration but not utilization or costs. In contrast, the
impact of diabetes on adjusted mean episode duration
(139.5 vs. 74.8 days with and without diabetes respec-
tively), number of services (16.8 vs. 9.9, p < .001), and
total episode charges ($3,473 vs. $1,482) was signiﬁcant
(p < .001), using uncomplicated trauma as an example.
The effects of post-operative complications were even
more pronounced (e.g., $6,908 vs. $1,482 for uncompli-
cated trauma episodes).
CONCLUSIONS: These ﬁndings suggest that accident
and injury payments should adjust for the impact of 
post-operative complications and diabetes on treatment
duration, intensity, and costs.
